<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">New and innovative funding is an active field of study, not just for viral hepatitis. WHO is holding a financing dialogue with its Member States and key non-State contributors, including a focus on sustainable financing and coordination to meet priority health needs generally in developing countries. Overall, however, donor funding for health is becoming increasingly scarce; add the need for sustainable and predictable funding and the task becomes even harder. Identifying the success factors and obstacles for these various mechanisms would contribute to the better definition of new funding mechanisms, as envisaged by VHPB and the International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA) [
 <xref ref-type="bibr" rid="CR15">15</xref>]. Key factors already identified include: political will (including the will to innovate); targeting with a tight focus (with clearly defined inputs and measurable outcomes); and effectiveness in both financial and medical terms of reference.
</p>
